Prestige Consumer Healthcare (NYSE:PBH) Receives "Buy" Rating from DA Davidson

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at DA Davidson in a note issued to investors on Monday,Benzinga reports. They presently have a $95.00 price target on the stock. DA Davidson's price objective suggests a potential upside of 16.21% from the company's current price.

Separately, Jefferies Financial Group reiterated a "hold" rating and issued a $76.00 price objective (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Prestige Consumer Healthcare has a consensus rating of "Moderate Buy" and an average target price of $94.20.

Prestige Consumer Healthcare Trading Up 1.7 %

Shares of PBH traded up $1.38 during trading hours on Monday, hitting $81.75. 242,658 shares of the stock were exchanged, compared to its average volume of 248,098. The firm has a market capitalization of $4.05 billion, a P/E ratio of 19.79, a price-to-earnings-growth ratio of 2.27 and a beta of 0.47. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 1.90. Prestige Consumer Healthcare has a fifty-two week low of $56.61 and a fifty-two week high of $82.00. The business has a 50-day moving average of $72.55 and a 200-day moving average of $69.84.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, hitting the consensus estimate of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The firm had revenue of $283.79 million during the quarter, compared to analyst estimates of $282.09 million. During the same period last year, the company posted $1.07 EPS. The business's quarterly revenue was down .9% on a year-over-year basis. On average, research analysts expect that Prestige Consumer Healthcare will post 4.44 EPS for the current year.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Hedge funds and other institutional investors have recently made changes to their positions in the business. State Board of Administration of Florida Retirement System increased its holdings in Prestige Consumer Healthcare by 77.4% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 25,221 shares of the company's stock worth $1,830,000 after purchasing an additional 11,000 shares in the last quarter. Lombard Odier Asset Management USA Corp bought a new stake in Prestige Consumer Healthcare during the second quarter worth $550,000. CANADA LIFE ASSURANCE Co raised its position in Prestige Consumer Healthcare by 19.4% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 47,575 shares of the company's stock valued at $3,453,000 after buying an additional 7,715 shares during the last quarter. Sequoia Financial Advisors LLC lifted its stake in Prestige Consumer Healthcare by 12.9% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 9,824 shares of the company's stock valued at $708,000 after acquiring an additional 1,120 shares in the last quarter. Finally, Atria Investments Inc purchased a new position in Prestige Consumer Healthcare during the 1st quarter worth $1,246,000. 99.95% of the stock is owned by institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.